Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin

@article{Maier1993Interleukin1MT,
  title={Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin},
  author={Steven F. Maier and Eric P. Wiertelak and David Martin and Linda R. Watkins},
  journal={Brain Research},
  year={1993},
  volume={623},
  pages={321-324}
}
Hypothalamic Mechanisms of Pain Modulatory Actions of Cytokines and Prostaglandin E2
Abstract: A decrease and subsequent increase in nociceptive threshold in the whole body are clinical symptoms frequently observed during the course of acute systemic infection. These biphasic changes
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1.
TLDR
The results suggest that the receptor mechanisms that mediate the behavioral and pyrogenic effects of IL-1 are heterogeneous, similar to other cytokines released during immune activation.
Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue
TLDR
An analgesic tripeptide analogue of IL-1β is developed which antagonizes hyperalgesia evoked by IL- 1β and by the inflammatory agent carrageenan.
Interleukin-1 induces analgesia in mice by a central action.
Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1.
  • A. Dunn
  • Biology, Medicine
    The Journal of pharmacology and experimental therapeutics
  • 1992
TLDR
The possibility that LPS acts by penetrating the brain was examined by comparing the neurochemical and corticosterone responses to i.p.c.v. LPS and IL-1, and the MHPG responses toIL-1 were substantially greater in hypothalamus than in other brain regions, whereas those to LPS were less regionally specific.
Functions and mechanisms of interleukin 1 in the brain.
  • N. Rothwell
  • Biology, Psychology
    Trends in pharmacological sciences
  • 1991
Interleukin-1 and interleukin-1 antagonism.
TLDR
The recent cloning of a naturally occurring IL-1 receptor antagonist (IL-1ra) has opened new experimental and clinical approaches and reduced the severity of diseases such as hemodynamic shock, lethal sepsis, inflammatory bowel disease, experimental arthritis, and the spontaneous proliferation of human leukemic cells.
...
1
2
3
...